(0.29%) 5 106.50 points
(0.63%) 38 623 points
(0.62%) 17 759 points
(0.32%) $79.20
(-0.79%) $2.02
(0.30%) $2 316.50
(0.56%) $26.98
(0.52%) $967.60
(-0.09%) $0.931
(-0.15%) $10.98
(-0.16%) $0.797
(0.93%) $91.98
5 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 13.16%
0.25% £ 2.04
Live Chart Being Loaded With Signals
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives...
Stats | |
---|---|
Dzisiejszy wolumen | 477 122 |
Średni wolumen | 2.73M |
Kapitalizacja rynkowa | 8.87M |
EPS | £0 ( 2023-08-31 ) |
Następna data zysków | ( £0 ) 2024-05-08 |
Last Dividend | £300.00 ( 2021-12-14 ) |
Next Dividend | £0 ( N/A ) |
P/E | -2.04 |
ATR14 | £0.0360 (1.74%) |
ImmuPharma PLC Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ImmuPharma PLC Finanse
Annual | 2022 |
Przychody: | £0 |
Zysk brutto: | £-117 563 (0.00 %) |
EPS: | £-0.0126 |
FY | 2022 |
Przychody: | £0 |
Zysk brutto: | £-117 563 (0.00 %) |
EPS: | £-0.0126 |
FY | 2021 |
Przychody: | £118 350 |
Zysk brutto: | £0.00 (0.00 %) |
EPS: | £-0.0325 |
FY | 2020 |
Przychody: | £126 667 |
Zysk brutto: | £0.00 (0.00 %) |
EPS: | £-0.0343 |
Financial Reports:
No articles found.
ImmuPharma PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £300.00 | 2021-12-14 |
Last Dividend | £300.00 | 2021-12-14 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | £300.00 | -- |
Avg. Dividend % Per Year | 240.00% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2021 | £300.00 | 2 400.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SEQI.L | Dividend Knight | 2023-07-27 | Quarterly | 10 | 3.85% | |
ICGC.L | Dividend Knight | 2023-09-14 | Annually | 15 | 1.80% | |
BISI.L | Dividend Knight | 2024-01-04 | Annually | 32 | 2.05% | |
WTB.L | Dividend Knight | 2023-05-25 | Annually | 33 | 0.87% | |
NTV.L | Dividend Knight | 2023-07-20 | Semi-Annually | 25 | 4.03% | |
EMG.L | Dividend King | 2023-08-10 | Semi-Annually | 31 | 3.60% | |
SPT.L | Dividend Knight | 2023-08-10 | Semi-Annually | 32 | 1.51% | |
JD.L | Dividend Knight | 2023-12-07 | Annually | 28 | 0.21% | |
BUT.L | Dividend King | 2023-08-03 | Quarterly | 49 | 1.28% | |
PNL.L | Dividend Knight | 2023-08-24 | Quarterly | 41 | 0.75% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -32.54 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.038 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.708 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.169 | 0.800 | 9.15 | 7.32 | [1 - 3] |
quickRatioTTM | 0.970 | 0.800 | 9.00 | 7.20 | [0.8 - 2.5] |
cashRatioTTM | 0.136 | 1.500 | -0.357 | -0.535 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.58 | 1.000 | -2.07 | -2.07 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00267 | -0.00533 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | -0.326 | 1.000 | -8.76 | -8.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -31.51 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0319 | 0.800 | -3.12 | -2.50 | [0.5 - 2] |
Total Score | -4.45 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.987 | 1.000 | -0.302 | 0 | [1 - 100] |
returnOnEquityTTM | -1.708 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00178 | -0.00533 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -3.28 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.93 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.03 |
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej